Cell and gene therapy (CGT) biotechnology company Ori Biotech has collaborated with contract development and manufacturing organization (CDMO) Charles River Laboratories (CRL) to accelerate cell-therapy production using the former firm’s CGT-manufacturing platform. According to Ori Biotech, the IRO platform reduces labor by up to 70%, costs by up to 50%, and process time by up to 25%. Earlier this year, CRL joined Ori’s LightSpeed Early Access Program (LEAP) designed to provide access…
Read More…
Charles River and Ori Biotech collaborate on CAR-T production
